Interleukin-5 in the Pathophysiology of Severe Asthma
Citations Over TimeTop 1% of 2019 papers
Abstract
Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Indeed, during the last years, significant advances have been made in our understanding of the cellular and molecular mechanisms underlying the powerful actions of IL-5 finalized to the induction, maintenance, and amplification of eosinophilic inflammation. Therefore, IL-5 is a suitable target for add-on biological therapies based on either IL-5 inhibition (mepolizumab, reslizumab) or blockade of its receptor (benralizumab). These modern treatments can result in being definitely beneficial for patients with severe type 2 (T2)-high eosinophilic asthma, refractory to conventional anti-inflammatory drugs such as inhaled and even systemic corticosteroids.
Related Papers
- → The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis(2020)193 cited
- → Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma(2018)182 cited
- Inhibition of interleukin-5 for the treatment of eosinophilic diseases.(2012)
- → Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts(2021)29 cited
- → Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab(2021)6 cited